QRx’s Dual Opioid Works In Phase III
This article was originally published in The Pink Sheet Daily
Australian specialty pharma takes aim at U.S. pain, CNS markets.
You may also be interested in...
Tamper-resistant version would lead to more problems, say FDA advisors.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.